Developments in the systemic therapy of pancreatic cancer

Cancer Investigation

Volumn 21, Issue 1, 2003, Pages 73-86

  El Rayes, B F ^a   Shields, A F ^a   Vaitkevicius, V ^a   Philip, Philip A ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Chemotherapy; Gemcitabine; Pancreatic cancer

Indexed keywords

7 HYDROXYSTAUROSPORINE; 9NC; ANGIOGENESIS INHIBITOR; BATIMASTAT; BRYOSTATIN 1; CAFFEINE; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; CYTARABINE; DNA POLYMERASE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; DRUG METABOLITE; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; FTI 2148; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE; IRINOTECAN; ISIS 2503; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; METHYLXANTHINE DERIVATIVE; MITOMYCIN C; NITROSOUREA DERIVATIVE; OXALIPLATIN; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SEMAXANIB; SN 398; STREPTOZOCIN; TAXANE DERIVATIVE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACCURACY; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; DUODENUM ULCER; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PANCREAS ADENOCARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; STEVENS JOHNSON SYNDROME; STOMACH ULCER; STOMATITIS; THROMBOCYTOPENIA; TUMOR VASCULARIZATION; VOMITING;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DIAGNOSTIC IMAGING; DNA TOPOISOMERASES, TYPE I; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FLUOROURACIL; HUMANS; NEOPLASM PROTEINS; PALLIATIVE CARE; PANCREATECTOMY; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; UNITED STATES;

EID: 0037214987     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120016406     Document Type: Review

References (86)

1. Greenlee, R.T.; Hill-Harmon, M.B.; Murray, T.; Thun, M. Cancer statistics. CA Cancer J. Clin. 2001, 51, 15-37.
2. Evans, D.B.; Abbruzzese, J.L.; Willett, C.G. Cancer of the pancreas. In Principles and Practice of Oncology, 6th Ed.; Devita, V.T., Hellman, S., Rosenberg, S.A., Eds.; Lippincott-Raven: Philadelphia, 2001; 1126-1162.
3. Geer, R.J.; Brennan, M.F. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am. J. Surg. 1993, 165, 68-73.
4. Smalley, S.R.; Macdonald, J.S. Pancreatic cancer. In Medical Oncology, 2nd Ed.; Calabres, P., Schein, P.S., Eds.; Mcgraw Hill: New York, NY, 1993; 691-712.
5. Cullinan, S.A.; Moertel, C.G.; Fleming, T.R.; Rubin, J.R.; Krook, J.E.; Everson, L.K.; Windschitl, H.K.; Twito, D.I.; Marschke, R.F.; Foley, J.F. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. J. Am. Med. Assoc. 1985, 253 (14), 2061-2067.
6. Casper, E.S.; Green, M.R.; Kelsen, D.P.; Heelan, R.T.; Brown, T.D.; Flombaum, C.D.; Trochanowski, B.; Tarassoff, P.G. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Investig. New Drugs 1994, 12 (1), 29-34.
7. Carmichael, J.; Fink, U.; Russell, R.C.; Spittle, M.F.; Harris, A.L.; Spiessi, G.; Blatter, J. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer 1996, 73 (1), 101-105.
8. Rothenberg, M.L.; Moore, M.J.; Cripps, M.C.; Andersen, J.C.; Portenoy, R.K.; Burris, H.A.; Green, M.R.; Tarassoff, P.G.; Brown, T.D.; Casper, E.S.; Storniolo, A.M.; Von Hoff, D. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann. Oncol. 1996, 7 (4), 347-353.
9. Rosenthal, M.L.; Burris, H.A.; Andersen, J.S.; Moore, M.; Green, M.R.; Portenoy, R.K. Gemcitabine: effective palliative therapy for pancreatic cancer patients failing 5-FU [abstract]. Proc. Am. Soc. Clin. Oncol. 1994, 14, 198.
10. Burris, H.A.; Moore, M.J.; Andersen, J.; Green, M.R.; Rothenberg, M.L.; Modiano, M.R.; Cripps, M.C.; Portenoy, R.K.; Storniolo, A.M.; Tarassoff, P.; Nelson, R.; Dorr, F.A.; Stephens, C.D.; Von Hoff, D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15 (6), 2403-2413.
11. Touroutoglou, N.; Gravel, D.; Raber, M.N.; Plunkett, W.; Abbruzzese, J.L. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann. Oncol. 1998, 9 (9), 1003-1008.
12. Tempero, M.; Plunkett. W.; Ruiz van Haperen, V.; Hainswort, J.; Hochster, H.; Lenzi, R.; Abbruzzese, J. Randomized Phase II Trail of Dose Gemcitabine Intense by Standard Infusion Vs. Fixed Dose Rate in Metastic Pancreatic Adenocarcinoma; Proc. Annu. Meet. Am. Soc. Clin. Oncol.: Atlanta, GA, May 15-18, 1999; 1048.
13. Wagener, D.J.; Verdonk, H.E.; Dirix, L.Y.; Catimel, G.; Siegenthaler, P.; Buitenhuis, M.; Mathieu-Boue, A.; Verweij, J. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann. Oncol, 1995, 6 (2), 129-132.
14. Stehlin, J.S.; Giovanella, B.C.; Natelson, E.A.; De Ipolyi, P.D.; Coil, D.; Davis, B.; Wolk, D.; Wallace, P.; Trojacek, A. A study of 9-nitrocamptothecin (RFS-20000) in patients with advanced pancreatic cancer. Int. J. Oncol. 1999, 14 (5), 821-831.
15. Rivkin, S.; Burris, H; Gerstein, H.; Reynolds, R.; Staddon, A.; Lenaz, L.; Marinaro, J.A.; Sun, S. A Phase II Study of Rubitecan (9NC) in Patients with Refractory Pancreatic Cancer; Proc. Annu. Meet. Am. Soc. Clin. Oncol.: New Orleans, LA, May 15-18, 2000; 1020.
16. Rougier, P.; Adenis, A.; Ducreux, M.; de Forni, M.; Bonneterre, J.; Dembak, M.; Clouet, P.; Lebecq, A.; Baille, P.; Lefresne-Soulas, F.; Blanc, C.; Armand, J.P. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur. J. Cancer 2000, 36 (8), 1016-1025.
17. Okada, S.; Sakata, Y.; Matsuno, S.; Kurihara, M.; Sasaki, Y.; Ohashi, Y.; Taguchi, T. Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan. Br. J. Cancer 1999, 80 (3-4), 438-443.
18. Oster, M.W.; Gray, R.; Panasci, L.; Perry, M.C. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM). Cancer 1986, 57 (1), 29-33.
19. The Gastrointestinal Tumor Study Group; Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. J. Clin. Oncol. 1986, 4 (12), 1794-1798.
20. Rougier, P.; Ducreux, M.; Douillard, J.Y.; Seitz, J.F.; Bugat, R.; Bosset, J.F.; Merouche, Y.; Raoul, J.L.; Ychou, M.; Adenis, A.; Cvitkovic Bertheau, F.; Luboinski, M.; Pignon, J.P. Efficacy of 5FU + cisplatin (FUP) compared to bolus 5FU (FU) in advanced pancreatic carcinoma (APC): a randomized trial from the French Anticancer Centers Digestive Group (FNLCCDG) St. Cloud; CHU, Besançon, France; Proc. Annu. Meet. Am. Soc. Clin. Oncol.: Atlanta, GA, May 15-18, 1999; 1050.
21. Kyriazis, A.P.; Kyriazis, A.A.; Yagoda, A. Enhanced therapeutic effect of cis-diamminedichloroplatinum (II) against nude mouse grown human pancreatic adenocarcinoma when combined with 1-beta-D-arabinofuranosylcytosine and caffeine. Cancer Res. 1985, 45, 6083-6087.
22. Dougherty, J.B.; Kelsen, D.; Kemeny, N.; Magill, G.; Botet, J.; Niedzwiecki, D. Advanced pancreatic cancer: a phase I-II trial of cisplatin, high-dose cytarabine, and caffeine. J. Natl Cancer Inst. 1989, 81 (22), 1735-1738.
23. Kelsen, D.; Hudis, C.; Niedzwiecki, D.; Dougherty, J.; Casper, E.; Botet, J.; Vinciguerra, V.; Rosenbluth, R. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer 1991, 68 (5), 965-969.
24. Ahmed, S.; Vaitkevicius, V.K.; Zalupski, M.M.; Du, W.; Arlauskas, P.; Gordon, C.; Kellogg, C.; Shields, A.F. Cisplatin, cytarabine, caffeine and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic carcinoma: a phase II study. Am. J. Clin. Oncol., 2000, 23, 420-424.
25. Plunkett, W.; Huang, P.; Searcy, C.E.;: Gandhi, V. Gemcitabine: preclinical pharmacology and mechanisms of action. Sem. Oncol. 1996, 23 (5 suppl. 10), 3-15.
26. Heinemann. V.; Wilke, H.; Mergenthaler, H.G.; Clemens, M.; Konig, H.; Illiger, H.J.; Arning, M.; Schalhorn, A.; Possinger, K.; Fink, U. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann. Oncol. 2000, II (11), 1399-1403.
27. Philip, P.A.; Zalupski, M.; Vaitkevicius, V.K.; Arlauskas, P.; Chaplen, R.; Heilbrun, L.K.; Adsay, V.; Weaver, D.; Sheilds, A. Phase II study of gemcitabine and cisplatin in advanced or metastatic pancreatic cancer. Cancer 2001, 92 (3), 569-577.
28. Colucci, G.; Riccardi, F.; Giuliani, F.; Lopez, M.; Gebbia, V.; Uomo, G.; Biglietto, M.; Cigolari, S.; Borsellino, N.; Paoletti, G.; Maiello, E.; Gebbia, N. Randomized trail of gemcitabine alone or with cisplatin in the treatment of advanced pancreatic cancer: a phase II multicenter study of the Southern Italy Oncology Group, Proc. Annu. Meet. Am. Soc. Clin. Oncol.: Atlanta, GA, May 15-18, 1999; 961.
29. Faivre, S.; Raymond, E.; Woynarows J.M.; Cvitkovic, E. Supraadditive effect of 2′2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother. Pharmacol. 1999, 44 (2), 117-123.
30. Louvet, C.; Andre, T.; Lledo, G.; Hammel, P.; Bleiberg, H.; Bouleuc, C.; Gamelin, E.; Fleasch, M.; Cvitkovic, E.; de Gramont, A. Gemcitabine-Oxaliplatin (GEMOX) combination in advanced pancreatic carcinoma (APC): a Gercor multicenter Phase II study. Proc. Annu. Meet. Am. Soc. Clin. Oncol.: San Francisco, CA, May 12-15, 2001; 506.
31. Hidalgo, M.; Castellano, D.; Paz-Ares, L.; Gravalos, C.; Diaz-Puente, M.; Hitt, R.; Alonso, S.; Cortes-Funes, H. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J. Clin. Oncol. 1999, 17 (2), 585-592.
32. Kurtz, J.E.; Kohser, F.; Negrier, S.; Trillet-Lenoir, V.; Walter, S.; Limacher, J.M.; Untereiner, M.; Kayitalire, L.; Jaeck, D.; Dufour, P. Gemcitabine and protracted 5-FU for advanced pancreatic cancer. A phase II study. Hepatogastroenterology 2000, 47 (35), 1450-1453.
33. Berlin, J.; Catalano, P.; Thomas, J.; Kluger, J.; Haller, D.G.; Benson, A.B., III. A phase III study of gemcitabine in combination with 5-FU vs. gemcitabine alone in patients with advanced pancreatic carcinoma (E2297): an Eastern Cooperative Oncology Group (ECOG) trial. Proc. Annu. Meet. Am. Soc. Clin. Oncol.: San Francisco, CA, May, 12-15, 2001; 505.
34. Rocha Lima, C.M.S.; Savarese, D.; Bruckner, H. Multi-center Phase II trial of first-line Irinotecan and Gemcitabine in patients with locally advanced of metastatic pancreatic cancer (PC). Proc. Annu. Meet. Am. Soc. Clin. Oncol.: New Orleans, LA, May 20-23, 2000; 263.
35. Stapthopoulos, G.; Rigatos, G.; Kouroussis, Ch.; Dimopoulos, M.; Panopoulos, C.; Giannakakis, T.; Tzanninis, D.; Georgoulias, V. Front-line treatment with gemcitabine in combination with Irinotecan: preliminary results of a multicenter Phase II study. Proc. Annu. Meet. Am. Soc. Clin. Oncol.: New Orleans, LA, May 20-23, 2000; 1260.
36. Burtness, B.; Argiris, A.; Rich, R.S.; Peccerillo, K.; Hall, M.; Gollerkeri, A.; Murren, J.R. Weekly chemotherapy with Irinotecan plus taxanes in advanced pancreatic cancer. Proc, Annu. Meet. Am. Soc. Clin. Oncol.: New Orleans, LA, May 20-23, 2000; 263.
37. Stathopoulos, G.P.; Mavroudis, D.; Tsavaris, N.; Kouroussis, C.; Aravantinos, G.; Agelaki, S.; Kakolyris, S.; Rigatos, S.K.; Karabekios, S.; Georgoulias, V. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann. Oncol. 2001, 12 (1), 101-103.
38. Sherman, W.H.; Fine, R.L. Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas. Oncology 2001, 60 (4), 316-321.
39. Moertel, C.G.; Childs, D.S.; Reitemeier, R.J.; Colby, M.Y.; Holbrook, M.A. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969, 2 (7626), 865-867.
40. Moertel, C.G.; Frytak, S.; Hahn, R.G.; O'Connell, M.J.; Reitemeier, R.J.; Rubin, J.; Schutt, A.J.; Weiland, L.H.; Childs, D.S.; Holbrook, M.A.; Lavin, P.T.; Livstone, E.; Spiro, H.; Knowlton, A.; Kalser, M.; Barkin, J.; Lessner, H.; Mann-Kaplan, R.; Ramming, K.; Douglas, H.O.; Thomas, P.; Nave, H.; Bateman, J.; Lokich, J.; Brooks, J.; Chaffey, J.; Corson, J.M.; Zamcheck, M.; Novak, J.W. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981, 48 (8), 1705-1710.
41. Gastrointestinal Tumor Study Group. Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer 1985, 56 (11), 2563-2568.
42. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J. Natl Cancer Inst. 1988, 80 (10), 751-755.
43. Klaassen, D.J.; Maclntyre, J.M.; Catton, G.E.; Engstrom, P.F.; Moertel, C.G. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil - an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 1985, 3 (3), 373-378.
44. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987, 59 (12), 2006-2010.
45. Foo, M.L.; Gunderson, L.L.; Nagorney, D.M.; McLlrath, D.C.; van Heerden, J.A.; Robinow, J.S.; Kvols, L.K.; Garton, G.R.; Martenson, J.A.; Cha, S.S. Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/- 5 fluorouracil. Int. J. Radiat. Oncol. Biol. Phys. 1993, 26 (3), 483-489.
46. Doyle, T.H.; Mornex, F.; McKenna, W.G. The clinical implications of gemcitabine radiosensitization. Clin. Cancer Res. 2001, 7 (2), 226-228.
47. Blackstock, A.W.; Bernard, J.W.; Richards, F.; Eagle, K.S.; Case, L.D.; Poole, M.E.; Savage, P.D.; Tepper, J.D. Phase 1 trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J. Clin. Oncol. 1999, 17 (7), 2208-2212.
48. McGinn, C.J.; Shureiqi, I.; Robertson, J.M.; Eckhauser, F.E.; Smith, D.C.; Decker, D.A.; Neumann, K.H.; Keller, B.; Brown, D.; Strawderman, M.; Lawrence, T.S. A phase I trial of radiation dose escalation with full dose gemcitabine in patients with pancreatic cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol.: Atlanta, GA, May 15-18, 1999; 1051.
49. Talamonti, M.S.; Catalano, P.J.; Vaughn, M.J.; Whittington, R.; Beauchamp, R.D.; Berlin, J.; Benson, A.B., III. Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J. Clin. Oncol. 2000, 18 (19), 3384-3389.
50. Safran, H.; Moore, T.; Iannitti, D.; Dipetrillo, T.; Akerman, P.; Cioffi, W.; Harrington, D.; Quirk, D.; Rathore, R.; Cruff, D.; Vakharia, J.; Vora, S.; Savarese, D.; Wanebo, H. Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 2001, 49 (5), 1275-1279.
51. Luo, J.; Guo, P.; Matsuda, K.; Truong, N.; Lee, A.; Chun, C.; Cheng, S.Y.; Korc, M. Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int. J. Cancer 2001, 92 (3), 361-369.
52. Davis, S.; Aldrich, T.H.; Jones, P.F.; Acheson, A.; Compton, D.L.; Jain, V.; Ryan, T.E.; Bruno, J.; Radziejewski, C.; Maisonpierre, P.C.; Yancopoulos, G.D. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996, 87 (7), 1161-1169.
53. Strydom, D.J.; Fett, J.W.; Riordan, J.F. The odyssey of angiogenin: a protein that induces blood vessel growth. Anal. Chem. 1989, 61 (20), 1173A-1179A.
54. Seo, Y.; Baba, H.; Fukuda, T.; Takashima, M.; Sugimachi, K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000, 88 (10), 2239-2245.
55. Ikeda, N.; Adachi, M.; Taki, T.; Huang, C.; Hashida, H.; Takabayashi, J.; Sho, M.; Nakajima, Y.; Kanehiro, H.; Hisanaga, M.; Nakano, H.; Miyake, M. Prognostic significance of angiogenesis in human pancreatic cancer. Br. J. Cancer 1999, 79 (9-10), 1553-1563.
56. Fujimoto, K.; Hosotani, R.; Wada, M.; Lee, J.U.; Koshiba, T.; Miyamoto, Y.; Tsuji, S.; Nakajima, S.; Doi, R.; Imamura, M. Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. Eur. J. Cancer 1998, 34 (9), 1439-1447.
57. Shishido, T.; Yasoshima, T.; Denno, R.; Mukaiya, M.; Sato, N.; Hirata, K. Inhibition of liver metastasis of human pancreatic carcinoma by angiogenesis inhibitor TNP-470 in combination with cisplatin. Jpn. J. Cancer Res. 1998, 89 (9), 963-969.
58. Williams, C.S.; Mann, M.; DuBois, R.N. The role of cyclooxygenases in inflammation, cancer and development. Oncogenes 1999, 18 (55), 7908-7916.
59. Molina, M.A.; Sitja-Arnau, M.; Lemoine, M.G.; Frazier, M.L.; Sinicrope, F.A. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999, 59 (17), 4356-4362.
60. Cao, Y.; Pearman, A.T.; Zimmerman, G.A.; McIntyre, T.M.; Prescott, S.M. Intracellular unesterified arachidonic acid signals apoptosis [In Process Citation]. Proc. Natl Acad. Sci. USA 2000, 97 (21), 11280-11285.
61. Tsujii, M.; Kawano, S.; DuBois, R.N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl Acad. Sci. USA 1997, 94 (7), 3336-3340.
62. Chiarugi, V.; Magnelli, L.; Gallo, O. COX-2, iNOS and p53 as play-makers of tumor angiogenesis. Int. J. Mol. Med. 1998, 2 (6), 715-719.
63. Koshiba, T.; Hosotani, R.; Wada, M.; Miyamoto, Y.; Fujimoto, K.; Lee, J.U.; Doi, R.; Arii, S.; Imamura, M. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer 1998, 82 (4), 642-650.
64. Haq, M.; Shafii, A.; Zervos, E.E.; Rosemurgy, A.S. Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer. Cancer Res. 2000, 60 (12), 3207-3211.
65. Bramhall, S.R.; Rosemurgy, A.; Brown, P.D.; Browry, C.; Buckels, J.A. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol. 2001, 19 (15), 3447-3455.
66. Sun, J.; Blaskovich, M.A.; Knowles, D.; Qian, Y.; Ohkanda, J.; Bailey, R.D.; Hamilton, A.D.; Sebti, S.M. Antitumor efficacy of a novel class of non-thiolcontaining peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, taxol, and gemcitabine. Cancer Res. 1999, 59 (19), 4919-4926.
67. Korc, M.; Chandrasekar, B.; Yamanaka, Y.; Friess, H.; Buchier, M.; Beger, H.G. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J. Clin. Investig. 1992, 90, 1352-1360.
68. Ozawa, F.; Friess, H.; Tempia-Caliera, A.; Kleeff, J.; Buchler, M.W. Growth factors and their receptors in pancreatic cancer. Teratog. Carcinog. Mutagen. 2001, 21, 27-44.
69. Ymanaka, Y.; Friess, H.; Kobrin, M.S.; Buchler, M.; Beger, H.G.; Korc, M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 1993, 13, 565-569.
70. Burtscher, I.; Compagni, A.; Lamm, G.; Christofori, G. An insulin-like growth factor-mediated, phosphatidylinositol 3′ kinase-independent survival signaling pathway in beta tumor cells. Cancer Res. 1999, 59 (16), 3923-3926.
71. Wagner, M.; Cao, T.; Lopez, M.E.; Hope, C.; van Nostrand, K.; Kobrin, M.S.; Fan, H.U.; Buchler, M.W.; Korc, M. Expression of a truncated EGF receptor is associated with inhibition of pancreatic cancer cell growth and enhanced sensitivity to cisplatinum. Int. J. Cancer 1996, 68, 782-787.
72. Overhosler, J.P.; Prewett, M.C.; Hooper, A.T.; Waksal, H.W.; Hicklin, D.J. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 2000, 89, 74-82.
73. Bruns, C.J.; Harbison, M.T.; Davis, D.W.; Portera, C.A.; Tsan, R.; McConkey, D.J.; Evans, D.B.; Abbruzzese, J.L.; Hicklin, D.J.; Radinsky, R. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res. 2000, 6 (5), 1936-1948.
74. Abbruzzese, J.; Rosenberg, A.; Xiong, Q.; LoBuglio, A.; Schmidt, W.; Wolff, R.; Needle, M.; Waksal, H. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody Cetuximab (IMC-C225) in combination with gemcitabine in patients advanced pancreatic cancer. Proc. ASCO 2001, 518a.
75. Nelson, J.M.; Fry, D.W. Inhibition of ERBB family receptors by CI-1033 enhances the cytotoxicity of gemcitabine via modulation of akt and MAP kinases. Proc. Am. Assoc. Cancer Res.: San Francisco, CA, April 1-5, 2000; 1533.
76. Ng, S.S.W.; Tsao, M.S.; Chow, S.; Hedley, D.W. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res. 2000, 60 (19), 5451-5455.
77. Shah, M.A.; Schwartz, G.K. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin. Cancer Res. 2001, 7, 2168-2181.
78. Tonkinson, J.L.; Worzalla, J.F.; Teng, C.H.; Mendelsohn, L.G. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res. 1999, 59 (15), 3671-3676.
79. Jung, C.P.; Motwani, M.V.; Schwartz, G.K. Flavopiridol increases sensitization to gemcitabine in human gastro-intestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin. Cancer Res. 2001, 7, 2527-2536.
80. Maisey, N.R.; Webb, A.; Flux, G.D.; Padhani, A.; Cummingham, D.C.; Ott, R.J.; Norman, A. FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. Br. J. Cancer 2000, 83 (3), 287-293.
81. Boral, A.L.; Dessain, S.; Chabner, B.A. Clinical evaluation of biologically targeted drugs: obstacles and opportunities. Cancer Chemother. Pharmacol. 1998, 42 (suppl), S3-21.
82. Kline, R.P.; Wu, E.X.; Petrylak, D.P.; Szabolcs, M.; Alderson, P.O.; Weisfeldt, M.L.; Cannon, P.; Katz, J. Rapid in vivo monitoring of chemotherapeutic response using weighted sodium magnetic resonance imaging. Clin. Cancer Res. 2000, 6 (6), 2146-2156.
83. Scheithauer, W.; Kornek, G.V.; Raderer, M.; Hejna, M.; Valencak, J.; Miholic, J.; Kovats, E.; Lang, F.; Funovics, J.; Bareck, E.; Depisch, D. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma. Br. J. Cancer 1999, 80 (11), 1797-1802.
84. Frey, C.; Twomey, P.; Keehn, R.; Elliott, D.; Higgins, G. Randomized study of 5-FU and CCNU in pancreatic cancer: report of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Study Group. Cancer 1981, 47 (1) 27-31.
85. Buroker, T.; Kim, P.N.; Groppe, C.; McCracken, J.; O'Bryan, R.; Panettiere, F.; Costanzi, J.; Bottomley, R.; King, G.W.; Bonnet, J.; Thigpen, T.; Whitecar, J.; Haas, C.; Vaitkevicius, V.K.; Hoogstraten, B.; Heilbrun, L. 5 F.U. infusion with mitomycin-C vs. 5 FU infusion with methyl-CCNU in the treatment of advanced upper gastrointestinal cancer: a Southwest Oncology Group Study. Cancer 1979, 44 (4), 1215-1221.
86. Reni, M.; Passoni, P.; Panucci, M.G.; Nicoletti, R.; Galli, L.; Balzano, G.; Zerbi, A.; Carlo Di, V.; Villa, E. Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. J. Clin. Oncol. 2001, 19 (10), 2679-2686.